Forte Biosciences Inc (FBRX)
0.739
+0.02
(+2.65%)
USD |
NASDAQ |
Apr 25, 16:00
Forte Biosciences Cash from Operations (TTM): -28.71M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -28.71M |
September 30, 2023 | -22.63M |
June 30, 2023 | -15.51M |
March 31, 2023 | -11.41M |
December 31, 2022 | -8.185M |
September 30, 2022 | -8.874M |
June 30, 2022 | -12.06M |
Date | Value |
---|---|
March 31, 2022 | -14.62M |
December 31, 2021 | -16.68M |
September 30, 2021 | -16.90M |
June 30, 2021 | -19.51M |
March 31, 2021 | -19.59M |
December 31, 2020 | -18.42M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-28.71M
Minimum
Dec 2023
-8.185M
Maximum
Dec 2022
-16.39M
Average
-16.68M
Median
Dec 2021
Cash from Operations (TTM) Benchmarks
CEL-SCI Corp | -23.07M |
AIM ImmunoTech Inc | -21.27M |
IGC Pharma Inc | -6.19M |
NovaBay Pharmaceuticals Inc | -4.131M |
Protalix BioTherapeutics Inc | -1.318M |